Released on = July 24, 2007, 7:58 am

Press Release Author = Press Release from La Merie Business Inteligence

Industry = Biotech

Press Release Summary = The best selling blockbuster drug in 2006 was atorvastatin
from Pfizer and Astellas Pharma with ww sales of US$ 13.6 bln. Biologics made 23.1 %
of the total blockbuster drug sales of US$ 233.7 bln generated by 114 blockbuster
drugs from 30 companies.

Press Release Body = BARCELONA, Spain | July 24, 2007 | The Business Intelligence
firm La Merie S.L. reported today that the HMG-CoA-reductase inhibitor atorvastatin
remained the no.1 best selling blockbuster drug in 2006 with ww sales of US$ 13.6
bln for Pfizer and Astellas Pharma. Among the TOP 10 blockbuster drugs are four
biologics (antibodies and proteins). A total of 114 distinct blockbuster drugs were
identified with 2006 sales of more than US$ 1 bln each. Total revenues from sales of
all blockbuster drugs in 2006 were US$ 233.7 bln of which 23.1 % were achieved by
biologics. The best selling classes of blockbuster drugs were again
HMG-Coa-reductase inhibitors of which AstraZeneca's rosuvastatin showed the highest
growth rate with 59 % over the previous year. Among the TOP 10 blockbuster drug
classes were three biologics: erythropoietin, anti-TNF and insulin & insulin
analogs. Blockbuster drugs were in the product portfolio of 30 biopharmaceutical
companies. Pfizer was the leader in the TOP 10 class of blockbuster drug companies
with sales of US$ 28.7 bln originating from nine blockbuster drugs. The TOP 10
companies had between four and 12 blockbuster drugs each to generate 2006 sales
between US$ 9.4 bln and 28.7 bln per company. These results and more were found in a
search conducted by La Merie Business Intelligence and published in a complimentary
report on July 6, 2007. The document entitled "Blockbuster Drugs 2006" can be
acquired as a free download at La Merie's News Center and Online Store
PipelineReview.com (www.pipelinereview.com).
The "Blockbuster Drugs 2006" report presents in tabular format 2006 sales figures of
the 114 blockbuster drugs with sales of more than US$ 1 bln each by company and for
a total of 30 companies. Further Tables summarize the TOP 10 list of companies with
blockbuster drugs in 2006, the TOP 10 best selling blockbuster drug classes as an
overview and the single blockbuster drugs by class. In addition, information is
provided on brand and generic names, target, class of compound, originator and
licensee companies, product category and major indications. All information is fully
referenced by a hyperlink leading to the original source of information.
About La Merie
La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high
quality R&D information to the biopharmaceutical industry. La Merie offers
individual consultancy services and publishes reports and periodicals. For more
information visit www.lamerie.com.
About PipelineReview.com
PipelineReview.com is the News Center and Online Store of La Merie Business
Intelligence focused on Research and Development in the Biopharmaceutical Industry.
Visitors of PipelineReview.com will find R&D relevant press releases and can receive
selected R&D news from one or more of the site's News Channels. A free R&D Newletter
conveniently brings via e-mail a daily selection of the most interesting news from
biopharmaceutical R&D. For more information visit www.pipelinereview.com.

Web Site = http://www.pipelinereview.com/joomla/content/view/13312/145/

Contact Details = Pau Cuevas
La Merie Business Intelligence
C/ Caspe, 33B, 4º, 2ª
E-08010 Barcelona
Tel +34-93-342 91 97
Fax +34-93-342 91 98
e-mail: pau.cuevas@lamerie.com
Website: http://www.lamerie.com
Online Store: www.pipelinereview.com